Skip to main content
GNPX
NASDAQ Life Sciences

Genprex 10-Q: Persistent Material Weaknesses, Going Concern Reiterated, and New Nasdaq MVLS Delisting Risk

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$5
Mkt Cap
$2.459M
52W Low
$4
52W High
$1,210
52W Position info
25% above low
Off High info
100% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

GNPX sits 25% above its 52-week low of $4.

Summary

Genprex's Q2 2026 10-Q reiterates going concern doubts, confirms unremediated material weaknesses, and flags a new Nasdaq delisting risk from the pending MVLS rule.


Key Events · Earnings and Guidance · GNPX

  • Material Weaknesses Unremediated

    Disclosure controls and procedures remain ineffective due to lack of segregation of duties and insufficient accounting personnel depth for complex transactions.

  • Going Concern Reiterated

    Substantial doubt about ability to continue as a going concern; cash of $15.15 million funds operations into H2 2027.

  • New Nasdaq MVLS Delisting Risk

    Market value of listed securities is below $5 million; if Nasdaq's pending MVLS rule becomes effective, the company could face immediate delisting without cure period.

  • Continued ATM Dilution

    Sold 353,095 shares for $15.6 million net proceeds in H1 2026, plus 241,000 shares for $1.53 million after quarter-end.


Analysis · GNPX · Life Sciences

Genprex's Q2 2026 10-Q confirms that material weaknesses in internal controls remain unremediated and reiterates substantial doubt about its ability to continue as a going concern. The company also discloses a new delisting risk: its market value of listed securities is below $5 million, which could trigger immediate delisting under Nasdaq's pending MVLS rule. Cash of $15.15 million funds operations into H2 2027, but the company continues to rely on dilutive ATM sales.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GNPX was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $4.00 to $1,210.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GNPX - Latest Insights

GNPX
Nov 13, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $2.08 info
Change: $0 (0%) info
Market Cap: $2.536M info
GNPX
Aug 03, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.65
Real-time Price: $2.08 info
Change: -$4.57 (-69%) info
Market Cap: $2.536M info
GNPX
Jul 30, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.50
Real-time Price: $2.08 info
Change: -$4.42 (-68%) info
Market Cap: $2.536M info
GNPX
Jul 14, 2026, 9:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.540
Real-time Price: $2.08 info
Change: Reverse Stock Split info
Market Cap: $2.536M info
GNPX
Jun 22, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $2.08 info
Change: Reverse Stock Split info
Market Cap: $2.536M info